Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Jeffrey S. Glenn:

Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. Deans RM et al. Nat Chem Biol. (2016)

HBV/HDV Coinfection: A Challenge for Therapeutics. Koh C et al. Clin Liver Dis. (2019)

Pathogenesis of and New Therapies for Hepatitis D. Koh C et al. Gastroenterology. (2019)

Search results

Items: 1 to 20 of 90

1.

Structure of the neurotensin receptor 1 in complex with β-arrestin 1.

Huang W, Masureel M, Qianhui Q, Janetzko J, Inoue A, Kato HE, Robertson MJ, Nguyen KC, Glenn JS, Skiniotis G, Kobilka BK.

Nature. 2020 Jan 16. doi: 10.1038/s41586-020-1953-1. [Epub ahead of print]

PMID:
31945771
2.

Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis.

Liu HL, Lv J, Zhao ZM, Xiong AM, Tan Y, Glenn JS, Tao YY, Weng HL, Liu CH.

Sci Rep. 2019 Dec 10;9(1):18719. doi: 10.1038/s41598-019-54663-4.

3.

HBV/HDV Coinfection: A Challenge for Therapeutics.

Koh C, Da BL, Glenn JS.

Clin Liver Dis. 2019 Aug;23(3):557-572. doi: 10.1016/j.cld.2019.04.005. Epub 2019 May 24. Review.

PMID:
31266627
4.

Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017.

Kim D, Adejumo AC, Yoo ER, Iqbal U, Li AA, Pham EA, Cholankeril G, Glenn JS, Ahmed A.

Gastroenterology. 2019 Oct;157(4):1055-1066.e11. doi: 10.1053/j.gastro.2019.06.026. Epub 2019 Jun 25.

PMID:
31251928
5.

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN).

J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27. Review.

PMID:
30982526
6.

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection.

Tsuge M, Uchida T, Walsh K, Ishida Y, Tateno C, Kumar U, Glenn JS, Koh C, Heller T, Uprichard SL, Dahari H, Chayama K.

Viruses. 2019 Mar 15;11(3). pii: E263. doi: 10.3390/v11030263.

7.

A functional subset of CD8+ T cells during chronic exhaustion is defined by SIRPα expression.

Myers LM, Tal MC, Torrez Dulgeroff LB, Carmody AB, Messer RJ, Gulati G, Yiu YY, Staron MM, Angel CL, Sinha R, Markovic M, Pham EA, Fram B, Ahmed A, Newman AM, Glenn JS, Davis MM, Kaech SM, Weissman IL, Hasenkrug KJ.

Nat Commun. 2019 Feb 15;10(1):794. doi: 10.1038/s41467-019-08637-9.

8.

The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection.

Townsend EC, Zhang GY, Ali R, Firke M, Moon MS, Han MAT, Fram B, Glenn JS, Kleiner DE, Koh C, Heller T.

J Gastroenterol Hepatol. 2019 Apr;34(4):764-775. doi: 10.1111/jgh.14617. Epub 2019 Feb 25.

PMID:
30695096
9.

Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia.

Mahale P, Aka P, Chen X, Pfeiffer RM, Liu P, Groover S, Mendy M, Njie R, Goedert JJ, Kirk GD, Glenn JS, O'Brien TR.

J Viral Hepat. 2019 Jun;26(6):738-749. doi: 10.1111/jvh.13065. Epub 2019 Feb 14.

PMID:
30661282
10.

Pathogenesis of and New Therapies for Hepatitis D.

Koh C, Heller T, Glenn JS.

Gastroenterology. 2019 Jan;156(2):461-476.e1. doi: 10.1053/j.gastro.2018.09.058. Epub 2018 Oct 18. Review.

11.

Human iPS derived progenitors bioengineered into liver organoids using an inverted colloidal crystal poly (ethylene glycol) scaffold.

Ng SS, Saeb-Parsy K, Blackford SJI, Segal JM, Serra MP, Horcas-Lopez M, No DY, Mastoridis S, Jassem W, Frank CW, Cho NJ, Nakauchi H, Glenn JS, Rashid ST.

Biomaterials. 2018 Nov;182:299-311. doi: 10.1016/j.biomaterials.2018.07.043. Epub 2018 Jul 27.

12.

Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States.

Kim D, Li AA, Perumpail BJ, Gadiparthi C, Kim W, Cholankeril G, Glenn JS, Harrison SA, Younossi ZM, Ahmed A.

Hepatology. 2019 Mar;69(3):1064-1074. doi: 10.1002/hep.30161. Epub 2019 Feb 11.

13.

Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016.

Kim D, Li AA, Gadiparthi C, Khan MA, Cholankeril G, Glenn JS, Ahmed A.

Gastroenterology. 2018 Oct;155(4):1154-1163.e3. doi: 10.1053/j.gastro.2018.07.008. Epub 2018 Sep 1.

14.

A new dual-targeting real-time RT-PCR assay for hepatitis D virus RNA detection.

Wang Y, Glenn JS, Winters MA, Shen LP, Choong I, Shi YL, Bi SL, Ma LY, Zeng H, Zhang FJ.

Diagn Microbiol Infect Dis. 2018 Oct;92(2):112-117. doi: 10.1016/j.diagmicrobio.2018.05.016. Epub 2018 May 29.

PMID:
29941366
15.

Hepatitis D Viremia Among Injection Drug Users in San Francisco.

Mahale P, Aka PV, Chen X, Liu P, Fram BJ, Wang AS, Simenel S, Tseng FC, Chen S, Edlin BR, Glenn JS, O'Brien TR.

J Infect Dis. 2018 May 25;217(12):1902-1906. doi: 10.1093/infdis/jiy157.

16.

Impact of Drug Overdose Deaths on Solid Organ Transplantation in the United States.

Cholankeril G, Li AA, Cholankeril R, Toll AE, Glenn JS, Ahmed A.

J Gen Intern Med. 2018 Sep;33(9):1423-1425. doi: 10.1007/s11606-018-4477-8. No abstract available.

17.

Emerging Therapeutic Targets for Hepatitis Delta Virus Infection.

Glenn JS.

Gastroenterol Hepatol (N Y). 2018 Jan;14(1):47-49. No abstract available.

18.

Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.

Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H.

Hepatol Commun. 2017 May 19;1(4):288-292. doi: 10.1002/hep4.1043. eCollection 2017 Jun.

19.

Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus.

Mahale P, Glenn JS, O'Brien TR.

Ann Intern Med. 2017 Nov 21;167(10):759-760. doi: 10.7326/L17-0476. No abstract available.

PMID:
29159388
20.

Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.

Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çalişkan A, Karatayli E, Karatayli S, Bozdayi AM, Koh C, Heller T, Idilman R, Glenn JS.

Hepatology. 2018 Apr;67(4):1224-1236. doi: 10.1002/hep.29658. Epub 2018 Feb 19.

PMID:
29152762

Supplemental Content

Loading ...
Support Center